Sunday, July 5, 2026

Knowledge Files How We Source Search

Via News Knowledge File

Novo Nordisk A/S

organization80% conf.·synced Jul 5, 2026

Pharmaceutical manufacturer of Wegovy (semaglutide) for weight management

50

sourced metrics

636

relationships

20

stated objectives

8

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Presence Countries

170countries

May 12, 2026source

Employee Presence Countries

80countries

May 12, 2026source

Year To Date Return

-29.4percent

Apr 1, 2026source

30 Day Return

0.9percent

Apr 1, 2026source

Valuation Score

5out_of_6

Apr 1, 2026source

7 Day Return

1.6percent

Apr 1, 2026source

Free Cash Flow

52100000000.0DKK

Apr 1, 2026source

1 Year Return

-43.1percent

Apr 1, 2026source

Stock Price

36.98USD

Apr 1, 2026source

Discount To Intrinsic Value

65.2percent

Apr 1, 2026source

Projected Free Cash Flow 2030

111.09billion_DKK

Apr 1, 2026source

Intrinsic Value Dcf

106.21USD

Apr 1, 2026source

Authorized Share Repurchase Limit

10percent

Mar 26, 2026source

Share Par Value

0.10DKK

Mar 26, 2026source

Final Dividend Per Share

7.95DKK

Mar 26, 2026source

Authorized Share Capital Increase

44650000DKK

Mar 26, 2026source

Dividend Per Share

11.70DKK

Mar 26, 2026source

Country Presence

80countries

Mar 25, 2026source

Stated objectives

Launch oral Wegovy formulation through pharmacies and telehealth providers

by 2026-01-01 00:00:00stated

Launch oral Wegovy pill in U.S. market

target: full_market_launch by 2026-01-01 00:00:00stated

Full U.S. launch of oral semaglutide in early January 2026

by 2026-01-01 00:00:00stated

Claw back ground lost to US rival Eli Lilly in weight-loss drug market

stated

Make Wegovy pill affordable and accessible to those who need it across multiple care channels

target: 70000+ US pharmacies by 2026-01-05 00:00:00stated

Provide affordable starting dose of Wegovy pill for self-pay patients

target: $149 per month ($5 per day) by 2026-01-05 00:00:00stated

Sales decline of 5% to 13% in 2026

target: -5% to -13% by 2026-12-31 00:00:00stated

Adjusted operating profit growth decline of 5% to 13% in 2026

target: -5% to -13% by 2026-12-31 00:00:00stated

2026 sales expected to fall

by 2026-12-31 00:00:00stated

Complete Phase III development of Ziltivekimab for inflammation-associated cardiovascular disease

stated

Relationship graph · 636 connections

Developed by

240

Competes with

129

Employs

44

regulates

37

headquartered in

28

Supplies to

23

Covered by

22

rates

9

Via News coverage

MACOM Technology Solutions Holdings And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Albany International Corporation And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Apache And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Novo Nordisk A/S And 4 Other Stocks Have Very High Payout Ratio

BanColombia S.A. And 7 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Hannon Armstrong Sustainable Infrastructure Capital And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Genmab And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

M.D.C. Holdings And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →